World Journal of Urology

, Volume 35, Issue 1, pp 11–20 | Cite as

Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage

  • J. J. WendlerEmail author
  • R. Ganzer
  • B. Hadaschik
  • A. Blana
  • T. Henkel
  • K. U. Köhrmann
  • S. Machtens
  • A. Roosen
  • G. Salomon
  • L. Sentker
  • U. Witzsch
  • H. P. Schlemmer
  • D. Baumunk
  • J. Köllermann
  • M. Schostak
  • U. B. Liehr
Invited Review


Irreversible electroporation (IRE), a new tissue ablation procedure available since 2007, could meet the requirements for ideal focal therapy of prostate cancer with its postulated features, especially the absence of a thermal ablation effect. Thus far, there is not enough evidence of its effectiveness or adverse effects to justify its use as a definitive treatment option for localized prostate cancer. Moreover, neither optimal nor individual treatment parameters nor uniform endpoints have been defined thus far. No advantages over established treatment procedures have as yet been demonstrated. Nevertheless, IRE is now being increasingly applied for primary prostate cancer therapy outside clinical trials, not least through active advertising in the lay press. This review reflects the previous relevant literature on IRE of the prostate or prostate cancer and shows why we should not adopt IRE as a routine treatment modality at this stage.


Focal therapy Ablation Irreversible electroporation Prostate Localized prostate cancer Definitive treatment 


Authors’ contributions

J. J. Wendler is the corresponding author, wrote the manuscript, collected and analyzed the data, and developed the project. R. Ganzer, B. Hadaschik, A. Blana, T. Henkel, K. U. Köhrmann, S. Machtens, A. Roosen, G. Salomon, L. Sentker, U. Witzsch, H. P. Schlemmer and J. Köllermann edited and critically revised the manuscript and voted for internal consensus. D. Baumunk wrote and edited the manuscript. M. Schostak is the chief of academy, wrote the manuscript and developed the project. U. B. Liehr is a senior author, wrote the manuscript and developed the project.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical standards

For this type of study (review) formal consent is not required.


  1. 1.
    Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29(27):3669–3676. doi: 10.1200/JCO.2011.34.9738 CrossRefPubMedGoogle Scholar
  2. 2.
    Schostak M, Köllermann J, Hadaschik B, Blana A, Ganzer R, Henkel T, Köhrmann KU, Liehr UB, Machtens S, Roosen A, Salomon G, Sentker L, Witzsch U, Schlemmer HP, Baumunk D (2015) Cancer control in focus insights and future perspectives for the focal treatment of prostate cancer. Aktuelle Urol 46(1):39–44. doi: 10.1055/s-0034-1396803 (Epub 2015 Feb 6)CrossRefPubMedGoogle Scholar
  3. 3.
    Kasivisvanathan V, Shah TT, Donaldson I, Kanthabalan A, Moore CM, Emberton M, Ahmed HU (2015) Focal therapy for prostate cancer: German version. Urologe A 54(2):202–209. doi: 10.1007/s00120-014-3668-0 (German)CrossRefPubMedGoogle Scholar
  4. 4.
    Davalos RV, Mir IL, Rubinsky B (2005) Tissue ablation with irreversible electroporation. Ann Biomed Eng 33(2):223–231CrossRefPubMedGoogle Scholar
  5. 5.
    Rubinsky B, Irreversible Electroporation (Book), Series in Biomedical Engineering, Springer, Berlin (2010). doi: 10.1007/978-3-642-05420-4. ISBN: 978-3-642-05419-8 (print) (online)
  6. 6.
    Davalos RV, Bhonsle S, Neal RE II (2015) Implications and considerations of thermal effects when applying irreversible electroporation tissue ablation therapy. Prostate 75(10):1114–1118. doi: 10.1002/pros.22986 (Epub 2015 Mar 23) CrossRefPubMedGoogle Scholar
  7. 7.
    Manual NanoKnife® System Procedure and Trouble Shooting Guide. Software version 2.2.0. AngioDynamics®, ©2011 AngioDynamics, Inc. P1-159Google Scholar
  8. 8.
    Golberg A, Bruinsma BG, Uygun BE, Yarmush ML (2015) Tissue heterogeneity in structure and conductivity contribute to cell survival during irreversible electroporation ablation by “electric field sinks”. Sci Rep 5:8485. doi: 10.1038/srep08485 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sano MB, Arena CB, Bittleman KR, DeWitt MR, Cho HJ, Szot CS, Saur D, Cissell JM, Robertson J, Lee YW, Davalos RV (2015) Bursts of bipolar microsecond pulses inhibit tumor growth. Sci Rep 13(5):14999. doi: 10.1038/srep14999 CrossRefGoogle Scholar
  10. 10.
    Valerio M, Ahmed HU, Emberton M (2015) Focal therapy of prostate cancer using irreversible electroporation. Tech Vasc Interv Radiol 18(3):147–152. doi: 10.1053/j.tvir.2015.06.005 (Epub 2015 Jun 18) CrossRefPubMedGoogle Scholar
  11. 11.
    Onik G, Mikus P, Rubinsky B (2007) Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 6(4):295–300CrossRefPubMedGoogle Scholar
  12. 12.
    Rubinsky J, Onik G, Mikus P, Rubinsky B (2008) Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J Urol 180(6):2668–2674. doi: 10.1016/j.juro.2008.08.003 (Epub 2008 Oct 31)CrossRefPubMedGoogle Scholar
  13. 13.
    Daniels C, Rubinsky B (2009) Electrical field and temperature model of nonthermal irreversible electroporation in heterogeneous tissues. J Biomech Eng 131(7):071006. doi: 10.1115/1.3156808 CrossRefPubMedGoogle Scholar
  14. 14.
    Golberg A, Rubinsky B (2010) A statistical model for multidimensional irreversible electroporation cell death in tissue. Biomed Eng Online 9:13. doi: 10.1186/1475-925X-9-13 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Korohoda W, Grys M, Madeja Z (2013) Reversible and irreversible electroporation of cell suspensions flowing through a localized DC electric field. Cell Mol Biol Lett 18(1):102–119. doi: 10.2478/s11658-012-0042-3 (Epub 2012 Dec 27)CrossRefPubMedGoogle Scholar
  16. 16.
    Qin Z, Jiang J, Long G, Lindgren B, Bischof JC (2013) Irreversible electroporation: an in vivo study with dorsal skin fold chamber. Ann Biomed Eng 41(3):619–629. doi: 10.1007/s10439-012-0686-1 (Epub 2012 Nov 22) CrossRefPubMedGoogle Scholar
  17. 17.
    Neal RE II, Smith RL, Kavnoudias H, Rosenfeldt F, Ou R, McLean CA, Davalos RV, Thomson KR (2013) The effects of metallic implants on electroporation therapies: feasibility of irreversible electroporation for brachytherapy salvage. Cardiovasc Intervent Radiol 36(6):1638–1645. doi: 10.1007/s00270-013-0704-1 (Epub 2013 Aug 14) CrossRefPubMedGoogle Scholar
  18. 18.
    Onik A, Rubinsky B (2010) Irreversible electroporation: first patient experience focal therapy of prostate cancer. Irreversible Electroporation (Book). Series in Biomedical Engineering, pp 235–247. Springer, Berlin. doi: 10.1007/978-3-642-05420-4. ISBN: 978-3-642-05419-8 (print), (online)
  19. 19.
    Neal RE II, Millar JL, Kavnoudias H, Royce P, Rosenfeldt F, Pham A, Smith R, Davalos RV, Thomson KR (2014) In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. Prostate 74(5):458–468. doi: 10.1002/pros.22760 (Epub 2014 Jan 17)CrossRefPubMedGoogle Scholar
  20. 20.
    Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, Allen C, Emberton M (2014) Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis 17(4):343–347. doi: 10.1038/pcan.2014.33 (Epub 2014 Sep 2) CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tomihama RT, Günther E, Kim D, Stehling M (2015) Irreversible electroporation treatment for prostate adenocarcinomas: a safety outcome study. J Vasc Interv Radiol 26(2):S121–S122. Abstract only. Published in issue: February, 2015Google Scholar
  22. 22.
    Murray K, Musser J, Mashni J, Srimathveeravalli G, Durack J, Solomon S, Coleman J (2015) PD47-08 irreversible electroporation (IRE) as a localized treatment for prostate cancer: a report on safety and outcomes. J Urol 193(4):e964. doi: 10.1016/j.juro.2015.02.2752 CrossRefGoogle Scholar
  23. 23.
    Niessen C, Jung EM, Beyer L, Pregler B, Dollinger M, Haimerl M, Scheer F, Stroszczynski C, Wiggermann P (2015) Percutaneous irreversible electroporation (IRE) of prostate cancer: contrast-enhanced ultrasound (CEUS) findings. Clin Hemorheol Microcirc 61(2):135–141. doi: 10.3233/CH-151985 CrossRefPubMedGoogle Scholar
  24. 24.
    Ting F, Tran M, Böhm M, Siriwardana A, Van Leeuwen PJ, Haynes AM, Delprado W, Shnier R, Stricker PD (2015) Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis 19(1):46–52. doi: 10.1038/pcan.2015.47 CrossRefPubMedGoogle Scholar
  25. 25.
    van den Bos W, de Bruin DM, Jurhill RR, Savci-Heijink CD, Muller BG, Varkarakis IM, Skolarikos A, Zondervan PJ, Laguna-Pes MP, Wijkstra H, de Reijke TM, de la Rosette JJ. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World J Urol. 2015 Aug 22. (Epub ahead of print)Google Scholar
  26. 26.
    van den Bos W, de Bruin DM, van Randen A, Engelbrecht MR, Postema AW, Muller BG, Varkarakis IM, Skolarikos A, Savci-Heijink CD, Jurhill RR, Zondervan PJ, Laguna Pes MP, Wijkstra H, de Reijke TM, de la Rosette JJ. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol. 2015 Oct 8. (Epub ahead of print)Google Scholar
  27. 27.
    Phillips MA, Narayan R, Padath T, Rubinsky B (2012) Irreversible electroporation on the small intestine. Br J Cancer 106(3):490–495. doi: 10.1038/bjc.2011.582 (Epub 2012 Jan 5) CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Schoellnast H, Monette S, Ezell PC, Single G, Maybody M, Weiser MR, Fong Y, Solomon SB (2013) Irreversible electroporation adjacent to the rectum: evaluation of pathological effects in a pig model. Cardiovasc Intervent Radiol 36(1):213–220. doi: 10.1007/s00270-012-0393-1 (Epub 2012 May 5) CrossRefPubMedGoogle Scholar
  29. 29.
    Srimathveeravalli G, Wimmer T, Monette S, Gutta NB, Ezell PC, Maybody M, Weiser MR, Solomon SB (2013) Evaluation of an endorectal electrode for performing focused irreversible electroporation ablations in the Swine rectum. J Vasc Interv Radiol 24(8):1249–1256. doi: 10.1016/j.jvir.2013.04.025 (Epub 2013 Jun 21) CrossRefPubMedGoogle Scholar
  30. 30.
    Schoellnast H, Monette S, Ezell PC, Maybody M, Erinjeri JP, Stubblefield MD, Single G, Solomon SB (2013) The delayed effects of irreversible electroporation ablation on nerves. Eur Radiol 23(2):375–380. doi: 10.1007/s00330-012-2610-3 (Epub 2012 Aug 16) CrossRefPubMedGoogle Scholar
  31. 31.
    Schoellnast H, Monette S, Ezell PC, Deodhar A, Maybody M, Erinjeri JP, Stubblefield MD, Single GW Jr, Hamilton WC Jr, Solomon SB (2011) Acute and subacute effects of irreversible electroporation on nerves: experimental study in a pig model. Radiology 260(2):421–427. doi: 10.1148/radiol.11103505 (Epub 2011 Jun 3)CrossRefPubMedGoogle Scholar
  32. 32.
    Li W, Fan Q, Ji Z, Qiu X, Li Z (2011) The effects of irreversible electroporation (IRE) on nerves. PLoS ONE 6(4):e18831. doi: 10.1371/journal.pone.0018831 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Månsson C, Nilsson A, Karlson BM (2014) Severe complications with irreversible electroporation of the pancreas in the presence of a metallic stent: a warning of a procedure that never should be performed. Acta Radiol Short Rep 3(11):2047981614556409. doi: 10.1177/2047981614556409. eCollection 2014 Dec
  34. 34.
    Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baère T, Dodd GD 3rd, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee FT Jr, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN; International Working Group on Image-Guided Tumor Ablation; Interventional Oncology Sans Frontières Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. J Vasc Interv Radiol 25(11):1691–1705.e4. doi: 10.1016/j.jvir.2014.08.027. (Epub 2014 Oct 23)
  35. 35.
    Brausi MA, Giliberto GL, Simonini GL, Botticelli L, Di Gregorio C (2011) 960 Irreversible electroporation (IRE), a novel technique for focal ablation of prostate cancer (PCA): results of a interim pilot study in low risk patients with PCA. Eur Urol Suppl. doi: 10.1016/S1569-9056(11)60942-1 Google Scholar
  36. 36.
    Van den Bos W, De Bruin DM, Veelo DP, Postema AW, Muller BG, Varkarakis IM, Skolarikos A, Zondervan PJ, Laguna Pes MP, Savci-Heijink CD, Wijkstra H, De Reijke TM, De La Rosette JJMCH (2015) Quality of life and safety outcomes following irreversible electroporation treatment for prostate cancer: results from a phase I–II study. J Cancer Sci Ther 7(10):312–321. doi: 10.4172/1948-5956.1000369 Google Scholar
  37. 37.
    Ting F, Van Leeuwen PJ, Stricker PD (2016) Step-by-step technique for irreversible electroporation of focal prostate cancer: an instructional video guide. J Vasc Interv Radiol 27(4):568. doi: 10.1016/j.jvir.2016.01.003 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • J. J. Wendler
    • 1
    Email author
  • R. Ganzer
    • 5
  • B. Hadaschik
    • 3
  • A. Blana
    • 4
  • T. Henkel
    • 6
  • K. U. Köhrmann
    • 7
  • S. Machtens
    • 8
  • A. Roosen
    • 9
  • G. Salomon
    • 10
  • L. Sentker
    • 11
  • U. Witzsch
    • 12
  • H. P. Schlemmer
    • 13
  • D. Baumunk
    • 1
  • J. Köllermann
    • 2
  • M. Schostak
    • 1
  • U. B. Liehr
    • 1
  1. 1.Department of Urology and Pediatric UrologyMagdeburg University Medical CenterMagdeburgGermany
  2. 2.Institute of PathologySana Medical Center OffenbachOffenbachGermany
  3. 3.Department of UrologyRuprecht-Karls UniversityHeidelbergGermany
  4. 4.Department of Urology and Pediatric UrologyMedical Center FürthNurembergGermany
  5. 5.Department of UrologyUniversity of LeipzigLeipzigGermany
  6. 6.Urological Practice of Dr. Henkel and Dr. KahmannBerlinGermany
  7. 7.Department of UrologySt. Theresa HospitalMannheimGermany
  8. 8.Department of UrologySt. Maria HospitalBergisch-GladbachGermany
  9. 9.Department of UrologyAugusta-Krankenanstalt gGmbH BochumBochumGermany
  10. 10.Martini ClinicHamburg-Eppendorf University Medical CenterHamburgGermany
  11. 11.Joint Urological PracticeSinsheimGermany
  12. 12.Department of Urology and Pediatric UrologyNorthwest Hospital & Medical CenterFrankfurt/MainGermany
  13. 13.Department of RadiologyGerman Cancer Research CenterHeidelbergGermany

Personalised recommendations